Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский
Data & Research

HHS Peptide Policy vs Real Use: What Tracker Data Shows

The six peptides HHS opened to compounding, compared with what Peptide Lab users actually track. Aggregate data, November 2026, free to cite.

Data window: July to 7 November 2026. Page published 7 November 2026. On 28 October 2026, the US Department of Health and Human Services (HHS) said it will not act against 503A pharmacies that compound six peptides (BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon) under strict conditions. This page compares that list with what people actually track in the Peptide Lab app. Every figure is a share of accounts that saved at least one vial, across several hundred accounts. No individual record is shown, no cell under 20 accounts is reported, and no dose figure is published.

📌 Journalists & writers: these figures are free to cite under CC BY 4.0. Suggested citation: Klow Peptide, "HHS Peptide Policy vs Real Use: What Tracker Data Shows," November 2026, https://klow-peptide.com/en/pages/hhs-peptide-policy-user-data/. Questions: [email protected].

Key findings

46%

of US accounts track at least one of the six peptides named by HHS

66%

of those US users only track them inside a blend such as KLOW, which the policy does not cover (single ingredient only)

84%

of US accounts track nothing that matches the policy's scope

46%

of US accounts track a GLP-1 family peptide. None is on the HHS list

28%

of all accounts track retatrutide, the most tracked peptide. It is still in clinical trials and not approved anywhere

16%

track GHK-Cu, the third most tracked entry. It is not on the HHS list either

How much of real use does the policy cover?

Track at least one of the six HHS-listed peptides
All42%
US46%
Track one of them as a single-ingredient entry (the only form the policy covers)
All23%
US16%
Track them only inside a blend or stack (outside the policy)
All20%
US30%
Track a GLP-1 family peptide (none is covered)
All43%
US46%
Track nothing that matches the policy's scope
All77%
US84%

Share of accounts that saved at least one vial. "US" = accounts located in the United States. Cells under 20 accounts are not reported.

Blends: the most common use falls outside the policy

The single-ingredient rule matters more than the list itself. In the US sample, two out of three accounts that track an HHS-listed peptide only track it inside a blend. The KLOW blend alone (BPC-157, TB-500, GHK-Cu and KPV in one vial) is tracked by 28% of US accounts, almost as many as retatrutide (29%).

Law firms that analysed the policy link the rule to safety monitoring: with one active ingredient per product, an adverse event can be traced to a specific substance. Whatever the reason, the result is the same: the most common way people use these peptides today stays outside the new pathway.

The six HHS-listed peptides, one by one

BPC-157
All34%
US38%
TB-500
All26%
US34%
KPV
All21%
US33%
MOTS-c
All5%
USbelow threshold
Semax
Allbelow threshold
USbelow threshold
Epitalon
Allbelow threshold
USbelow threshold

Counts an account once per peptide, whether it tracks the peptide alone or inside a blend. TB-500 and KPV reach these levels mostly through the KLOW blend (BPC-157, TB-500, GHK-Cu, KPV).

What people track most, and what the list leaves out

Retatrutidenot covered: GLP-1, not approved
All28%
KLOW blendblend: outside the policy
All18%
GHK-Cunot on the list
All16%
Tirzepatidenot covered: approved drug
All13%
BPC-157on the list
All12%
CJC-1295 / Ipamorelinnot on the list
All6%
MOTS-con the list
All5%

Share of accounts that track each entry, all countries. Single-ingredient TB-500, KPV, Semax and Epitalon entries are each below the reporting threshold.

GLP-1 peptides: half of users, none covered

Close to half of all accounts (43%, and 46% in the US) track a GLP-1 family peptide: retatrutide, tirzepatide, semaglutide, cagrilintide or survodutide. The policy covers none of them. Retatrutide alone (28%) is tracked by more accounts than any HHS-listed peptide as a single entry. It is still in phase 3 trials and is not approved in any country, so it cannot be compounded legally in the US.

Tirzepatide and semaglutide are approved drugs. Their compounding follows separate FDA rules that tightened after the shortages ended, and the HHS policy does not change them.

What the HHS policy covers

The policy is narrow. HHS says it does not intend to take enforcement action when a state-licensed pharmacy, a federal facility or a licensed physician compounds one of six listed peptide bulk substances under section 503A, and only when a set of conditions is met at the same time. The main ones:

  • a valid patient-specific prescription;
  • a substance from an FDA-registered manufacturer, with a lot-level certificate of analysis;
  • a route of administration set for each peptide (for example, intranasal only for Semax, topical or oral only for KPV);
  • a single active ingredient per compounded product. A product that combines BPC-157 and TB-500 is outside the policy, even though both peptides are on the list.

The policy is interim: it lasts until each substance is addressed in a final rule on the 503A bulks list. Compounded drugs remain unapproved by the FDA. For the full text and context, see our news report on the policy, Are peptides legal? (with the US rules) and compounded vs research-use peptides.

Methodology

  • Source: the Peptide Lab production database (web and Android app), read-only, on 7 November 2026. Accounts created from July 2026. Guest-mode usage (data stored only on the device) is not included.
  • Base: accounts that saved at least one vial, excluding admin and test accounts. Several hundred accounts in total; the US share is a large minority of them. Country comes from the account's location data.
  • Threshold: any cell with fewer than 20 accounts is reported as "below threshold". Compound names were normalized (case, spacing, common misspellings) before counting.
  • HHS-listed: BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon. A blend counts for each listed peptide it contains (KLOW: BPC-157, TB-500, KPV; GLOW and Wolverine: BPC-157, TB-500). "Single-ingredient entry" means the vial holds one listed peptide and nothing else.
  • GLP-1 family: retatrutide, tirzepatide, semaglutide, cagrilintide, survodutide (same definition as Peptide Lab Data 2026).
  • What tracking means: a vial saved in a tracking app. It does not show where the product came from, whether it was prescribed or compounded, or whether it was used as entered.
  • Limits: an early-adopter sample from one app. It describes people who use a tracker, not the whole market. The policy is ten days old: this page is a baseline, and we plan to repeat the measure in early 2027.
  • Privacy: aggregates only. No email, name, note, dose or individual log was read or exported.

Nothing on this page is medical or legal advice. This site does not give dosing guidance.

Frequently Asked Questions

Which peptides does the HHS policy cover?
Six peptide bulk substances: BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, each with a set route of administration. The policy applies to 503A compounding only, with a patient-specific prescription, a registered manufacturer, a lot-level certificate of analysis and one active ingredient per product.
Does the policy cover blends like KLOW or BPC-157 + TB-500?
No. HHS limits the policy to compounded products with a single active ingredient. A product that combines two listed peptides, such as BPC-157 and TB-500, is outside it. In our US sample, two out of three accounts that track an HHS-listed peptide only track it inside a blend.
Are GLP-1 peptides such as retatrutide included?
No. No GLP-1 family peptide is on the list. Retatrutide, the most tracked peptide in our data (28% of accounts), is still in clinical trials and is not approved in any country.
Can I cite these figures?
Yes. All figures on this page are free to cite for editorial and research use under a CC BY 4.0 license. Attribute them to Klow Peptide with a link to this page. For questions, write to [email protected].
How many accounts are in the sample?
Several hundred accounts that saved at least one vial in the Peptide Lab app. We publish percentages only, and any cell with fewer than 20 accounts is reported as below threshold.